A Phase 2 interventional study of LDE225 and TMZ in Medulloblastoma, sponsored by Novartis Pharmaceuticals. Completed at 41 sites in 13 countries. Open to participants aged 4 Months and older. Per ClinicalTrials.gov, last updated 2017-08-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 245 studies in Medulloblastoma with a site in United States — 26 open to participants now, 53 under way, 2 of them phase 3. Medulloblastoma · United States.
Among the 245 studies in Medulloblastoma with a site in United States, this one is the 136th largest by enrollment of the 215 interventional ones that give a count, is one of 11 that started in 2013, is one of 65 in phase 2, and was the 135th registered.
317 studies on the registry are indexed under Medulloblastoma; 51 are open to participants now.
Browse Medulloblastoma studies →26 of the 245 studies in Medulloblastoma with a site in United States are open now. Recruiting first, the newest first:
Robbie Majzner · Sites in United States
Ages 2–21
Sabine Mueller, MD, PhD · Sites in United States
Ages 1–25
St. Jude Children's Research Hospital · Sites in United States
Ages 10–25
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 3–22
University of Florida · Sites in United States
Ages 4–39
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 31 (84%) stop at 75 or younger; 34 take children under 18; 1 takes healthy volunteers.
This study: 4 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
245 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 137 · Phase 2 87 · Phase 3 11 · Phase 4 2
First in 1992; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 31 across 255 interventional studies indexed under Medulloblastoma.
Median enrollment 30 across the 215 interventional studies, 139 across the 15 observational. Of the 181 that completed or were terminated, 57 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 245 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Medulloblastoma — fewer than ten, so there is no comparison to draw.
11 of the studies in Medulloblastoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04337177Valent Technologies, LLCFlavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | 2026-12 |
| NCT04661384City of Hope Medical CenterBrain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | 2027-01-12 |
| NCT06701812H. Lee Moffitt Cancer Center and Research InstituteDigoxin Medulloblastoma Study | 2027-02 |
| NCT04541082Jazz PharmaceuticalsPhase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | 2027-03-31 |
| NCT04185038Seattle Children's HospitalStudy of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | 2027-05 |
Add all 11 to your calendar (.ics) → With an account.
Among the 245 studies in Medulloblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase II study evaluated the safety and efficacy of LDE225 in adult and pediatric patients with Hh-pathway activated, relapsed MB.
This study was a single-arm study of the efficacy and safety of oral sonidegib in patients with Hh-pathway activated relapsed medulloblastoma. It was initially designed as a randomized, controlled, open-label phase III study of adults and children with Hh-pathway activated MB whose disease had failed standard of care therapy, including radiation therapy (RT). The original study consisted of a randomized controlled part and a non-randomized uncontrolled part. Approximately 69 patients were to be randomized in a 2:1 ratio to receive sonidegib oral suspension or the active control, temozolomide (TMZ) capsules. Randomization was to be stratified according to age, \<18 years versus ≥ 18 years. Approximately 40 patients were to receive sonidegib in the non-randomized uncontrolled part of the study. Following the enrollment of 11 patients, the study was amended to become a phase II single-arm study with only sonidegib, and the target enrollment was changed to 20 patients. Prior to the study amendment, TMZ participants whose disease progressed while on TMZ were permitted to crossover to sonidegib. After the amendment, participants receiving TMZ were crossed over to sonidegib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Performance Status corresponding to score of 0, 1, or 2:
Adequate bone marrow function as defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
600 mg orally for adults and 500 mg/m2 orally for children
Drug: LDE225
150 to 200 mg/m2 for 5 sequential days every 4 weeks according to prescribing information until the study was amended to a single arm study.
Drug: TMZ
Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) (as per tumor response guidelines and criteria for Medulloblastoma). The IRC evaluated all radiological images and applicable clinical data (i.e., neurological examination, steroid use and cerebrospinal fluid (CSF) results as applicable). Assessments after crossover were not included for TMZ participants.
Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Progression Free Survival (PFS) According to IRC From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
PFS was defined as the time from date of randomization to the date of event defined as the first documented progression or death due to any cause (as per tumor response guidelines and criteria for Medulloblastoma). The IRC evaluated all radiological images and applicable clinical data (i.e., neurological examination, steroid use and cerebrospinal fluid (CSF) results as applicable). TMZ participants without event prior to crossover were censored.
Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
PFS According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
PFS was defined as the time from date of randomization to the date of event defined as the first documented progression or death due to any cause. PFS was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma.
Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Percentage of Participants With ORR According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR). ORR was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma. Assessments after crossover were not included for TMZ patients.
Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Duration of Response (DoR) According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
DoR was defined as the time from the first documented onset of confirmed PR or CR to the date of PD/relapse or death due to medulloblastoma. DoR was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma. TMZ participants without an event prior to crossover were censored.
Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Overall Survival (OS) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
OS was defined as the time from date of randomization to date of death due to any cause. All deaths are considered, including deaths occurred after crossover for TMZ participants.
Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Pharmacokinetics (PK): Summary of Plasma Trough Concentrations for Sonidegib (LDE225)
Blood samples were collected for assessment. The children's group was analyzed up until week 25 only.
Time frame: Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 and 53
| Milestone | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Temozolomide (TMZ) |
|---|---|---|---|
| Started | 2 | 16 | 4 |
| Pharmacokinetic analysis set | 2 | 13 | 0 |
| Completed | 1 | 14 | 3 |
| Not completed | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Milestone | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Temozolomide (TMZ) |
|---|---|---|---|
| Started | 1 | 10 | 0 |
| Completed | 1 | 10 | 0 |
| Not completed | 0 | 0 | 0 |
ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) (as per tumor response guidelines and criteria for Medulloblastoma). The IRC evaluated all radiological images and applicable clinical data (i.e., neurological examination, steroid use and cerebrospinal fluid (CSF) results as applicable). Assessments after crossover were not included for TMZ participants.
| Percentage of participants | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Temozolomide (TMZ) |
|---|---|---|---|
| Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016 | 0.0 | 18.8 | 0.0 |
PFS was defined as the time from date of randomization to the date of event defined as the first documented progression or death due to any cause (as per tumor response guidelines and criteria for Medulloblastoma). The IRC evaluated all radiological images and applicable clinical data (i.e., neurological examination, steroid use and cerebrospinal fluid (CSF) results as applicable). TMZ participants without event prior to crossover were censored.
| months | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Temozolomide (TMZ) |
|---|---|---|---|
| Progression Free Survival (PFS) According to IRC From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016 | 1.6 (NA to NA) | 3.3 (1.7 to 17.1) | 2.9 (0.9 to 4.0) |
PFS was defined as the time from date of randomization to the date of event defined as the first documented progression or death due to any cause. PFS was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma.
| months | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Temozolomide (TMZ) |
|---|---|---|---|
| PFS According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016 | NA (1.6 to NA) | 3.3 (1.6 to 13.0) | 2.9 (0.9 to 4.0) |
ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR). ORR was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma. Assessments after crossover were not included for TMZ patients.
| Percentage of participants | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Temozolomide (TMZ) |
|---|---|---|---|
| Percentage of Participants With ORR According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016 | 0.0 | 25.0 | 0.0 |
DoR was defined as the time from the first documented onset of confirmed PR or CR to the date of PD/relapse or death due to medulloblastoma. DoR was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma. TMZ participants without an event prior to crossover were censored.
| months | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Temozolomide (TMZ) |
|---|---|---|---|
| Duration of Response (DoR) According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016 | NA (NA to NA) | 8.5 (4.1 to 16.6) | NA (NA to NA) |
OS was defined as the time from date of randomization to date of death due to any cause. All deaths are considered, including deaths occurred after crossover for TMZ participants.
| months | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Temozolomide (TMZ) |
|---|---|---|---|
| Overall Survival (OS) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016 | NA (4.5 to NA) | 9.5 (4.9 to 15.6) | NA (1.2 to NA) |
Blood samples were collected for assessment. The children's group was analyzed up until week 25 only.
| ng/mL | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults |
|---|---|---|
| Week 1 (n=2,11) | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 3 (n=2,10) | 2890 ± 1240 | 761 ± 519 |
| Week 5 (n=2,8) | 4930 ± 1380 | 1090 ± 700 |
| Week 7 (n=1,8) | 2810 ± NA | 1450 ± 842 |
| Week 9 (n=1,8) | 4670 ± NA | 1530 ± 682 |
| Week 13 (n=1,4) | 3680 ± NA | 2330 ± 1100 |
| Week 17 (n=1,6) | 3060 ± NA | 1880 ± 730 |
| Week 21 (n=1,5) | 3770 ± NA | 2270 ± 915 |
| Week 25 (n=1,4) | 1890 ± NA | 2050 ± 625 |
| Week 29 (n=NA,4) | NA ± NA | 2050 ± 906 |
| Week 33 (n=NA,4) | NA ± NA | 2180 ± 512 |
| Week 37 (n=NA,3) | NA ± NA | 2850 ± 306 |
| Week 41 (n=NA,4) | NA ± NA | 2370 ± 916 |
| Week 45 (n=NA,2) | NA ± NA | 2890 ± 290 |
| Week 49 (n=NA,2) | NA ± NA | 2330 ± 990 |
| Week 53 (n=NA,2) | NA ± NA | 2080 ± 764 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sonidegib (LDE225) Children | — | 2/2 (100%) | 2/2 (100%) |
| Sonidegib (LDE225) Adults | — | 9/16 (56.3%) | 16/16 (100%) |
| Sonidegib (Total) | — | 11/18 (61.1%) | 18/18 (100%) |
| Temozolomide (TMZ) | — | 1/4 (25%) | 4/4 (100%) |
| Event | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Sonidegib (Total) | Temozolomide (TMZ) |
|---|---|---|---|---|
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 1/2 | 0/16 | 1/18 | 0/4 |
| THROMBOSIS IN DEVICEProduct Issues | 1/2 | 0/16 | 1/18 | 0/4 |
| NECK PAINMusculoskeletal and connective tissue disorders | 0/2 | 0/16 | 0/18 | 1/4 |
| VOMITINGGastrointestinal disorders | 0/2 | 2/16 | 2/18 | 0/4 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 0/2 | 2/16 | 2/18 | 0/4 |
| NAUSEAGastrointestinal disorders | 0/2 | 1/16 | 1/18 | 0/4 |
| PAINGeneral disorders | 0/2 | 1/16 | 1/18 | 0/4 |
| BACTERIAL SEPSISInfections and infestations | 0/2 | 1/16 | 1/18 | 0/4 |
| CLOSTRIDIAL INFECTIONInfections and infestations | 0/2 | 1/16 | 1/18 | 0/4 |
| LUNG INFECTIONInfections and infestations | 0/2 | 1/16 | 1/18 | 0/4 |
| Event | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Sonidegib (Total) | Temozolomide (TMZ) |
|---|---|---|---|---|
| VOMITINGGastrointestinal disorders | 2/2 | 7/16 | 9/18 | 1/4 |
| HEADACHENervous system disorders | 2/2 | 3/16 | 5/18 | 1/4 |
| ALOPECIASkin and subcutaneous tissue disorders | 2/2 | 6/16 | 8/18 | 0/4 |
| NAUSEAGastrointestinal disorders | 0/2 | 5/16 | 5/18 | 3/4 |
| DIARRHOEAGastrointestinal disorders | 1/2 | 3/16 | 4/18 | 0/4 |
| FATIGUEGeneral disorders | 0/2 | 7/16 | 7/18 | 2/4 |
| ORAL HERPESInfections and infestations | 1/2 | 0/16 | 1/18 | 0/4 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 1/2 | 7/16 | 8/18 | 1/4 |
| BLOOD CREATINE PHOSPHOKINASE MB INCREASEDInvestigations | 1/2 | 1/16 | 2/18 | 1/4 |
| MYALGIAMusculoskeletal and connective tissue disorders | 1/2 | 5/16 | 6/18 | 0/4 |
| Age, Continuous(Years) | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Temozolomide (TMZ) | Total |
|---|---|---|---|---|
| Median | 8.5 ± 6.36 | 37.0 ± 8.17 | 35.5 ± 3.16 | 35.0 ± 10.73 |
| Sex: Female, Male(Participants) | Sonidegib (LDE225) Children | Sonidegib (LDE225) Adults | Temozolomide (TMZ) | Total |
|---|---|---|---|---|
| Female | 2 | 5 | 2 | 9 |
| Male | 0 | 11 | 2 | 13 |
Ran from May 2013 to primary completion in Oct 2016, 40 months.
Results were first posted in Jun 2017, 8 months after primary completion.
Of 42 phase 2 interventional studies under Medulloblastoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 92. This study's 40 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonidegib